Introduction
============

The vitamin D system comprises a group of fat-soluble prohormones and their various metabolites. It has been eminent for its role in calcium homeostasis and maintenance of bone metabolism (Holick, 2007). Low levels of vitamin D are found in a great part of the population leading some authorities to state a worldwide epidemic of vitamin D deficiency and to recommend vitamin D supplementation. Concerns about vitamin D deficiency rose when further research revealed cancer patients had lower levels of serum 25(OH)D (25-hydroxyvitamin D), and study subjects using vitamin D had lower rates of cancers and fewer markers of inflammation (Neuhouser et al., 2008; Mohr et al., 2014). Considerable data propose that the adding calcitriol to several chemotherapy regimens intensify the activity of such treatments and possibly a better response level to the regimens (Ma et al., 2010).

Studies suggested that inflammation mediates the initiation and progression of tumors, angiogenesis, and metastasis in patients with cancer. Epidemiological studies have shown that low 25(OH)D levels are associated with higher levels of systemic inflammation (Ngo et al., 2010; Crowley, 2014). Additionally, recent studies demonstrate the power of vitamin D supplementation to lower inflammation and oxidative stress biomarkers, by operating at the DNA level to regulate genes to reduce inflammation (Chen et al., 2014). These data remain debated, a recent meta-analysis had no success to show the helpful effects of vitamin D supplementation on inflammatory cytokines (Jamka et al., 2015). Moreover, in an animal study, vitamin D deficiency increased over the three-fold burden of liver tumor growth in the context of TGF-β (Transforming growth factor beta 1) (Chen et al., 2016). In another survey, TAC (total antioxidant capacity) levels decrease 35% in the serum of patients with cancer breast undergoing chemotherapy (Omar et al., 2011).

Vitamin D performs its biological activities through binding to the VDR (vitamin D receptor), a particular high-affinity receptor. VDR is a member of nuclear receptors for steroid hormones and controls gene expression as a ligand-activated transcription factor (2012). The VDR gene has more than 460 SNPs (single nucleotide polymorphisms) that have the regulatory role on 1, 25(OH)~2~D~3~. Hence, they can be assumed as a predictor of cell reply to supplementation in different conditions (Abd-Elsalam et al., 2015). Four types of VDR polymorphisms consisting FokI, BsmI, ApaI, and TaqI have more association with breast cancer (Hutchinson et al., 2000; Newcomb et al., 2002). Therefore, it is predicted that increasing 25(OH)D may improve the concentrations of TAC parallel with reducing blood inflammatory markers.

A clinical trial showed that 4 weeks supplementation with 200,000 IU of vitamin D~3~ administered as a single dose improved the serum 25(OH)D and TAC levels and significantly lower the us-CRP (Ultra-Sensitive CRP) levels in old females with vitamin D insufficiency. The serum concentrations of 25(OH)D and us-CRP of participants with the BB/Bb genotype were more susceptible to supplementation (de Medeiros Cavalcante et al., 2015). An epidemiological study examined the risk of breast cancer related to polymorphism of VDR gens and 25 (OH)D in plasma. TaqI, one of the VDR polymorphism, reduced the risk of breast cancer by 26% (Reimers et al., 2015). In another study serum levels of 25 (OH)D of individuals with genetic variation of vitamin D receptor protein responded differently to vitamin D~3~ supplements (Nimitphong et al., 2013).

Despite the epidemiological evidence, there are no published trials regarding the effects of vitamin D supplementation on blood levels of 25 (OH)D, TNF-α, TGF-β1, and TAC in accordance with the different variation of VDR polymorphism among breast cancer women. Based on this purpose, we conducted a randomized, double-blind, placebo-controlled trial of vitamin D~3~ supplementation to estimate the changes of total 25 (OH)D over 2 months based on VDR genotypes.

Materials and Methods
=====================

*Study population*

Who were followed up at the oncology ward, University Golestan Medical Center, between April to September 2015. Medical Research Ethics Committee at the Ahvaz Jundishapur University of Medical Science approved the study. Patients with metastatic breast cancer and those who had histories of other cancers, history of chemotherapy, radiotherapy, and hormone therapy for any reasons except current cancer, treating with corticosteroids, chronic diarrhea and malabsorption were excluded. Patients with known inflammatory conditions (such as acute bacterial or viral infections), autoimmune diseases (such as rheumatoid arthritis or lupus) were also excluded from the study. Patients were undergo chemotherapy at the beginning of study. The sample size of 23 was calculated for each group by considering significance level of P \< 0.05 and power of 80% (Hopkins et al., 2011). Applying 20% dropout, a sample size of 28 for the placebo and intervention groups was yielded.

###### 

Baseline Characteristics of the Clinical Trial Participants

                                       Treatment group                         
  ------------------------------------ ------------------- ------------------- ------
                                       n=26                n=26                
  Demographics                                                                 
  Age, y                               46.3 (9.5)          47.7 (8.0)          0.6
  Ethnicity,%                                                                  
  Arab                                 54                  43.5                
  Fars                                 46                  56.5                0.46
  Breast cancer Stage, %                                                       
  I                                    33                  27                  
  II                                   42                  43                  
  III                                  25                  30                  0.5
  Anthropometric                                                               
  BMI                                  29.2 ± 6.3          30.2 ± 5.4          0.59
  Waist circumference                  103.5 ± 12.5        109 ± 11.2          0.12
  Mean dietary intakes                                                         
  Total energy intake, kcal/d          1,596 ± 528         1,848 ± 821         0.59
  Total fat, g/d                       67 ± 32             70 ± 32             0.59
  Dietary calcium, mg/d                618 ± 308           843 ± 526           0.41
  Dietary fiber, g/d                   15 ± 7              18 ± 9              0.97
  Dietary carotenoid intake (μg/day)   4743.74 ± 4771.63   4509.17 ± 3890.52   0.77
  Dietary vitamin C intake (mg/day)    104.16 ± 79.14      108.80 ± 84.43      0.16
  Dietary vitamin E intake (mg/day)    30.7 ± 18.28        29.8 ± 15.36        0.53
  Dietary selenium intake (μg/day)     48.5 ± 29.77        46.9 ± 27.63        0.68

Data are given as means±SD unless otherwise specified;

Chi square test was used for categorical variables; Independent t-test was used for continuous variables.

###### 

Change in Biomarkers of Serum after Supplementation of Vitamin D in Breast Cancer Patients

  Biomarkers          Placebo     Vitamin D   Absolute treatment effect [a](#TFN3){ref-type="table-fn"}                                                                                           
  ------------------- ----------- ----------- ----------------------------------------------------------- ------------ ----------- --------------------------------------- ---------- ----------- ---------------------------------------
  25 (OH) D (ng/mL)   15.3±2.2    13.4±2.2    0.59                                                        28±2.6       39±3.5      0.004[\*](#TFN2){ref-type="table-fn"}   -1.9±0.9   11±3.1      0.001[\*](#TFN2){ref-type="table-fn"}
  TNF-α (pg/mL)       32.6±8      25.6±3.2    0.19                                                        13.4±1.1     14.5±1.6    0.96                                    7.0±2.1    1.1±2.1     0.18
  TGF-β (pg/mL)       123.4±9     133.8±10    0.24                                                        293.8±48.8   288±42.9    0.84                                    10.4±7.1   -5.6±33.4   0.64
  TAC (U/ml)          45.2±11.5   29.2±8.3    0.001[\*](#TFN2){ref-type="table-fn"}                       48.9±13.3    63.5±13.3   0.004[\*](#TFN2){ref-type="table-fn"}   -16±8.4    14.6±8.9    0.017[\*](#TFN2){ref-type="table-fn"}

Values are Mean±SD;

p value \< 0.05;

Absolute treatment effect is the absolute change from baseline to follow-up in the treatment group minus the absolute change from baseline to follow-up in the placebo group;

P values for differences between the treatment and placebo groups;

P values for difference between baseline visit and post-intervention values; 25 (OH)D, 25-hydroxyvitamin D; TNF-α, tumor Necrosis Factor alpha; TGF- β1, transforming growth factor beta 1; TAC, total antioxidant capacity.

###### 

Changes in TNF-α Levels with Regards to VDR Polymorphism in Breast Cancer Patient[\*](#TFN6){ref-type="table-fn"}

         Placebo   Vitamin D   Absolute treatment effect [a](#TFN7){ref-type="table-fn"}                                                                     
  ------ --------- ----------- ----------------------------------------------------------- ------ ---- ---------- ---------- ------- ------------ ---------- -------
  FokI                                                                                                                                                       
  FF     3         7.5±0.5     39.5±14.5                                                   0.51   3    13.0±1.0   28.0±12    0.42    32.0±14.0    15.0±11    0.7
  Ff     19        38.5±1.7    24.8±3.6                                                    0.12   18   14±1.3     12.7±1.3   0.27    -13.7±9.9    -1.3±2     0.23
  ff     4         11.67±1.2   20.67±8.4                                                   0.27   5    8.5±1.5    18.0±5.0   0.24    9.0±9.0      9.5±3.5    0.34
  BsmI                                                                                                                                                       
  BB     7         40.4±28.1   16.0±27                                                     0.4    5    9.0±1.4    11.0±1.4   0\. 4   -24.4±29.8   2.0±0      0.4
  Bb     11        32.6±12     22.2±3.3                                                    0.27   15   15.0±1.4   14.2±1.6   0.5     -10.4±11     -0.8±2.5   0.4
  bb     8         27.7±8.2    36.0±7.4                                                    0.5    6    10.5±1.4   19.2±7.0   0.3     8.3±9.0      8.7±6      0.97
  ApaI                                                                                                                                                       
  AA     11        15.4±2.8    26.6±4.2                                                    0.13   10   13.6±1.3   14.8±3.2   0.95    11.2±5.6     1.2±3.5    0.17
  Aa     11        51.0±15.8   23.0±5.8                                                    0.08   10   12.7±1.3   13.5±1.6   0.95    -28.0±15.4   0.8±2.0    0.094
  aa     4         25.5±13.5   32.0±7.0                                                    0.6    6    14.6±4.2   15.8±4.5   0.98    6.5±6.5      1.2±7.4    0.7
  TaqI                                                                                                                                                       
  TT     8         21.0±6.2    15.8±3.9                                                    0.4    7    16.5±4.6   11.5±1.2   0.32    -5.2±7.6     -5.0±5.1   0.98
  Tt     15        41.6±12.2   29.4±4.7                                                    0.3    13   13.7±1.0   15.9±16    0.68    -12.2±13     2.2±3      0.29
  tt     3         14.0±2.6    22.6±5.3                                                    0.5    6    10.8±2.0   13.4±3.0   0.69    8.6±7.6      2.6±4      0.53

\* Values are Mean±SD;

p value\< 0.05;

Absolute treatment effect is the absolute change from baseline to follow-up in the treatment group minus the absolute change from baseline to follow-up in the placebo group;

P values for difference between treatment group and placebo group;

P values for difference between follow-up visit and baseline visit; TNF-α, Tumor Necrosis Factor alpha; VDR, vitamin D receptor.

###### 

Changes in TGF-β Levels with Regards to VDR Polymorphism in Breast Cancer Patient

         Placebo   Vitamin D    Absolute treatment effect [a](#TFN11){ref-type="table-fn"}                                                                      
  ------ --------- ------------ ------------------------------------------------------------ ------ ---- ----------- ---------- ------ ----------- ------------ ------
  FokI                                                                                                                                                          
  FF     3         169.6±45     183.6±39                                                     0.31   3    245±125     277±127    0.18   14.0±14.0   32.0±2.0     0.55
  Ff     19        116.8±8.6    124.3±10                                                     0.5    18   293.8±58    289.5±51   0.89   7.5±8.5     -4.3±39.2    0.77
  ff     4         116.5±8.5    150±30                                                       0.38   5    341±60      285±65     0.72   33.5±21.5   -56.0±125    0.6
  BsmI                                                                                                                                                          
  BB     7         116.4±5.8    140.6±21.4                                                   0.3    5    220.5±305   280±80     0.69   24.2±18.7   59.5±110.5   0.8
  Bb     11        146.8±12     148.3±14.6                                                   0.9    15   313±67.7    320±59.4   0.88   1.5±4.2     7.1±43.2     0.9
  bb     8         109.7±17     95.5±15.4                                                    0.51   6    253±73.9    197±16.5   0.45   14.2±17.6   -56.0±67     0.37
  ApaI                                                                                                                                                          
  AA     11        120.1±19.8   131.6±20.5                                                   0.47   10   334±103     278±69     0.31   11.5±12.8   -56.0±53.0   0.25
  Aa     11        123.8±3.4    134.0±10                                                     0.41   10   225.5±30    239.2±34   0.7    10.2±9.6    13.7±32.6    0.91
  aa     4         138.5±2.5    145.5±9.5                                                    0.6    6    344±120     394±146    0.68   7.0±7.0     50.0±110     0.71
  TaqI                                                                                                                                                          
  TT     8         140.8±30     139.4±31                                                     0.6    7    431±229     347±154    0.4    -1.4±6.1    -84±87.0     0.41
  Tt     15        111.7±9.4    124.5±11                                                     0.33   13   284.2±52    282.6±56   0.94   12.8±10.8   -1.6±38.0    0.7
  tt     3         146.7±22     164±31.9                                                     0.5    6    222.9±29    260.5±66   0.68   17.3±19     37.6±84.2    0.87

p value\< 0.05;

treatment effect is the absolute change from baseline to follow-up in the treatment group minus the absolute change from baseline to follow-up in the placebo group;

P values for difference between treatment group and placebo group;

P values for difference between follow-up visit and baseline visit; TGF- β1, transforming growth factor beta 1; VDR, vitamin D receptor.

###### 

Changes in TAC Levels with Regards to VDR Polymorphism Following Vitamin D Supplementation in Breast Cancer Patient

  Genotype   Placebo   Vitamin D   Absolute treatment effect [a](#TFN15){ref-type="table-fn"}                                                                        
  ---------- --------- ----------- ------------------------------------------------------------ ------- ---- ----------- ----------- ------ ------------ ----------- ----------------------------------------
  FokI                                                                                                                                                               
  FF         3         51.6.±41    50.0±41.5                                                    0.15    3    96.5.±86    164.5±5.5   0.59   -1.6±1.6     68.0±92     0.58
  Ff         19        39.2±11.4   27.7±8.7                                                     0.1     18   43.0±13.9   53.1±13.6   0.12   -11.3±7.8    10.1±5.7    0.036[\*](#TFN14){ref-type="table-fn"}
  ff         4         92.0±81.0   10.0±4.0                                                     0.48    5    54.5±38.5   56.0±37.0   0.79   -82±81.0     1.5±1.5     0.41
  BsmI                                                                                                                                                               
  BB         7         48.8±25.6   46.6±22.5                                                    0.42    5    114.0±91    120±99      0.64   -2.2±4.7     6.0±8.0     0.4
  Bb         11        52.7±17.9   35.5±14.5                                                    0.18    15   39.0±14.6   47.4±12     0.32   -17.2±13     8.3±7.1     0.08
  bb         8         9.5±1.6     32.3±20.0                                                    0.25    6    34.0±19.7   76±35.6     0.37   -22.8±20     42.0±39.3   0.12
  ApaI                                                                                                                                                               
  AA         11        50.0±19.4   31.9±14.8                                                    0.19    10   25.0±9.7    55.6±19.6   0.18   -18.1±14.5   30.6±19.9   0.06
  Aa         11        46.1±16.2   29.1±11.0                                                    0.19    10   56.8±26     64.4±25     0.38   17±13.5      7.6±7.1     0.15
  aa         4         12.5±0.5    14.0±1.0                                                     0.79    6    72.4±31.6   74.4±26     0.94   1.5±1.5      2.0±14.2    0.98
  TaqI                                                                                                                                                               
  TT         8         62.2±31     57.8±30                                                      0.047   7    13.7±3.0    19.3±1.2    0.14   -4.4±2.2     5.6±2.0     0.02[\*](#TFN14){ref-type="table-fn"}
  Tt         15        48.2±15.1   23.2±8.4                                                     0.072   13   37.3±13.7   57±15.7     0.17   -25±13.8     19.7±12.8   0.03[\*](#TFN14){ref-type="table-fn"}
  tt         3         12.6±1.4    16.0±4.5                                                     0.84    6    91.6±34.8   99.5±32     0.66   3.4±5.8      7.8±14.9    0.84

Values are Mean±SD;

p value \< 0.05;

Absolute treatment effect is the absolute change from baseline to follow-up in the treatment group minus the absolute change from baseline to follow-up in the placebo group;

P values for difference between treatment group and placebo group;

P values for difference between follow-up visit and baseline visit; TAC, total antioxidant capacity; VDR, vitamin D receptor.

*Study design*

This study was an 8 week parallel, randomized, double-blind, placebo-controlled trial of vitamin D~3~supplementation in breast cancer women. Participants were assigned to 2 treatment arms: placebo and vitamin D~3~ through a 2 months intervention period. Randomized block design method was exerted for grouping to receive either 50,000 IU/week (provided by Zahravi Pharm. Co., Tabriz, Iran) or edible paraffin as placebo. All capsules were indistinguishable in shape and color. Each subject was sequentially assigned a number upon study entry while all participants and investigators were blinded throughout the study. Recruitment began from March to April 2015 and the sampling was completed in September. At the beginning, gave their written informed consents, completed the questionnaires and were interviewed. Five milliliters of serums were collected from all subjects. Compliance was checked by calling the patients every week. Subjects were visited by the oncologist at the beginning and at 8th week post-intervention. After two months, blood samples were re-collected for measurement of serum 25 (OH)D concentrations and VDR polymorphism. Blood samples were drawn into two tubes for serum and CBC (complete blood count) and then immediately placed on ice and covered from light. Serum and plasma samples were separated by centrifuge with 2,000 RMP for 16 min using a 46H centrifuge (HETTIC, FRANCE). The serum samples were stored at -70 ^o^C freezer for further analyses. The levels of 2 different serum cytokines (TNF-α, TGF-β1) and total antioxidant capacity were measured at the baseline and the final visit by ELISA (enzyme-linked immunosorbent assay) method. VDR polymorphism including ApaI ،BsmI ،FokI, and TaqI of all subject was genotyped by SSP-PCR (Polymerase Chain Reaction with Sequence-Specific Primers) technique. The four SNPs of VDR are located in exon 2, intron 8, intron 8 and exon 9 of chromosome 12 (12q12-q14), respectively. Mean of 3-day energy and nutrients intake were analyzed using Nutritionist IV Database Manager 4.0 software. A trained nutritionist performed all data entrance.

*Laboratory Tests*

ELISA kits of bioactiva diagnostica GmbH Company (Homburg, Germany) were used to analyze serum TNF-α, TGF-β1 and TAC according to the manufacturer's protocol. Different VDR gene polymorphisms were assessed by SSP-PCR technique (Lombard et al., 2006; Søborg et al., 2007). DNA was extracted by using commercial DNA extraction Kit (Roach, USA) from blood specimens. PCR reaction was implemented. After that, the product of PCR reaction electrophoresis was done on Agarose gel 1.5%. Allele frequencies and genotype polymorphism of the VDR gene were determined. Treatment groups were compared for basic characteristics and endpoint. Mean 25(OH)D concentrations were measured for the both groups at baseline and after 2-month follow-up.

Medical Research Ethics Committee at the Ahvaz Jundish apur University of Medical Science approved the study protocol. All participants signed the written informed consent.

*Statistical analysis*

Both treatment groups were assessed for comparing the characteristics at baseline and final follow-up visit using the Chi suare sample t for categorical variables and Independent t-test and paired T-test for continuous variables. The normality checked by using the Mann-Whitney test and Wilcoxon. Treatment effects were evaluated by assessing the differences in TNF-α, TGF-β1, and TAC concentrations from baseline to 2-month follow-up between the treatment and the placebo groups. All statistical analyses were performed with SPSS version 24. A P value of less than 0.05 was considered statistically significant.

Results
=======

A total of 125 patients were screened that led to the enrollment of 56 eligible patients; patients were randomly assigned to receive vitamin D~3~ (n=28) and placebo (n=28) for 2 months. The trial ended in September 2015. Four patients (8%) withdrew from the study: 2 patients in the vitamin D~3~ group and 2 in the control group due to side effects (n = 1), unwillingness to continue participation (n = 1), diagnosing metastasis (n =1), and consuming Ca/vitamin D pills (n = 1). Consequently, 26 patients in the vitamin D~3~ group and 26 patients in the placebo group finished the trial. Compliance rate was 95.6% patient in the vitamin D~3~ group and 91.6% patients in the placebo group and it was not significant. Baseline characteristics of the participant were similar between the supplemented and placebo groups ([Table 1](#T1){ref-type="table"}).The mean age of the participants was 47±8.8 y. From all subjects 49% were Arab and 51% were Fars. The dietary intake of participants at baseline and 2 months after supplementation using three 24-hour recalls indicated no significant differences between the groups.

As indicated in [Table 2](#T2){ref-type="table"}, the mean of 25(OH)D increased from 28 to 39 ng/mL in vitamin D group (P = 0. 004). The mean of TAC decreased from 45.2 to 29.2 U/ml in the placebo while it increased from 48.9 to 63.5 U/ml in vitamin D group. These increase and decrease were significant. Accordingly, the mean of increase was 14.6 U/ml in supplemented group and mean of reduction was 16 U/ml in placebo group (p≤0.04). The effect of vitamin D~3~on the both inflammatory markers i.e. TNF-α, TGF-β1 was not significantly different compared to the placebo group.

Individuals were classified according to their VDR genotypes to evaluate the changes in the inflammatory factors TNF-α ([Table 3](#T3){ref-type="table"}) and TGF-β1 ([Table 4](#T4){ref-type="table"}) and TAC ([Table 5](#T5){ref-type="table"}). The effects of vitamin D~3~ on TNF-α, TGF-β1 of the most reported VDR subgroups showed degrees of decrease, however, changes were not statistically significant ([Table 3](#T3){ref-type="table"}, [Table 4](#T4){ref-type="table"}). Supplementation significantly increased the serum TAC levels in TT, Tt cases (p ≤0.03) but not tt subgroup. Additionally, the serum TAC levels significantly elevated in Ff individuals (p = 0.036) but not FF/ff subjects. Despite medium increment of TAC among AA genotype, no significant changes were found in the subgroup (P=0.06). The other variables did not significantly change.

Discussion
==========

This study examine the impact of oral high-dose vitamin D~3~ supplementation on circulating inflammatory markers and TAC according to four VDR polymorphisms (i.e. BsmI, ApaI, TaqI, and FokI) in women with breast cancer. Serum levels of 25(OH)D and TAC elevated in treatment group. Despite a reduction trend seen in TNF-α, and TGF-β1 concentration, we did not find any significant impacts of vitamin on these biomarkers. Also, the serum TNF-α, and TGF-β1 levels did not show any differences with regard to VDR genotype following supplementation. However, TAC concentrations of individuals with the TT/Tt, and Ff genotypes significantly elevated post-intervention.

The interaction of supplementation and inflammatory markers was evaluated. Available evidence is extremely limited about regulating role of vitamin D on serum cytokines among breast cancer women. Our results are similar to another study by Jorde et al., (2010) that found no changes in inflammatory markers following vitamin D supplementation of 20,000 IU/week or 40,000 IU/week of D~3~ in overweight subjects. Chandler et al., (2014) also observed in African Americans that using three doses of vitamin D~3~ including 1,000, 2,000, or 4,000 IU/day orally for 3 months could not reduce the CRP, IL-6, IL-10, and sTNF-R2 (soluble TNF receptor 2) levels after supplementation period. On the contrary, one-year supplementation with vitamin D decreased serum IL-6 levels while hs-CRP (high sensitivity- CRP) levels were significantly increased and TNF-α did not respond to supplementation in overweight subjects (Beilfuss et al., 2012). Administration of vitamin D~3~ doses of 2,000 IU per day for three months did not affect 10 different cytokines (IL-2, 4, 5, 6, 8, 10, 13, IFN-γ, TNF-α) in healthy adults (Yusupov et al., 2010). A significant reduction was observed in the serum TGF-β levels at the 8th week in vitamin D deficient PCOS women who received 50,000 of vitamin D~3~ supplementation once weekly (Irani et al., 2015).

Researches on cancer patients have reported different findings. Serum inflammatory markers may moderately be a nonspecific measurement of short-term differences in tissue-specific inflammatory pathways that are importance in breast cancer (Reeves et al., 2011). Some RCTs have indicated significant favorable effects of vitamin D supplementation on inflammatory cytokines such as IL-6, sTNF-R2, and CRP, but only in precisely chosen groups of diabetics patient (Shab-Bidar et al., 2012) and patients with colorectal adenoma (Hopkins et al., 2011). Additionally, The role of TGFβ-1 in cancer progression has been shown to be multifaceted, depending on the tumor stage (Parvani et al., 2011). This cytokine acts as a potential growth inhibitor during beginning and development of cancer. TGF-β1 is also regarded as a metastasis stimulator, contributing to malignant progression (Zarzynska, 2014). Surprisingly, the majority of carcinogenic cells lose sensitivity to the inhibitory effect and initiate to secrete TGF-β1 when entering the phase of uncontrollable growth (Boulanger et al., 2005). This may be the reason for observing no significant changes in blood concentration of TGF-β1.

Vitamin D deficiency or insufficiency is prevalent among women with breast cancer indicating that dietary intake and sun exposure are not sufficient for maintaining adequate levels of this vitamin (Alipour et al., 2014; Bidgoli and Azarshab, 2014). This deficiency might be related to TAC levels and its function (Gargari et al., 2016). The Endocrine Society (2011) has suggested that supplementation doses should be 50,000 IU of vitamin D~2~ or D~3~ for vitamin D deficient individuals (Holick et al., 2011). A recent meta-analysis revealed that vitamin D~3~ is more capable of improving serum 25(OH)D~3~ concentrations when administering as a high oral dose (50,000 IU single dose or 300,000 IU single dose, and 50,000 IU/month) in comparison to prescription of daily dose of D~2~, but the influence was lost with 1,000-4,000 IU/d supplementation (Tripkovic et al., 2012). A retrospective study showed weekly high-dose supplementation statistically improved 25(OH)D~3~levels Compared to the no-supplementation group though daily low-dose supplementation was failed to increase 25(OH)D~3~ levels significantly. This study involved women with stage 1--3 breast cancer who have different cancer treatment (radiotherapy, chemotherapy, and/or hormone therapy).

In the line with our study, de Medeiros et al., (2015) showed that 4 weeks of supplementation with 200,000 IU of vitamin D~3~ administered as a single dose significantly improved serum 25(OH)D levels and total antioxidant capacity in elderly women with vitamin D insufficiency. Similar results have been indicated in diabetic patients who took vitamin D~3~-fortified butter-milk containing 170 mg calcium and 500 IU/250 ml twice a day for 12 weeks (Shab-Bidar et al., 2015b). In contrast to ours, some studies did not find any effects of vitamin D supplementation on TAC. In diabetic women, supplementation with 50,000 IU vitamin D~3~ for 6 weeks did not affect TAC concentrations (Asemi et al., 2013). Similar result was observed in pregnant women who consumed 50,000 IU vitamin D for 6 weeks from weeks 24--28 of pregnancy up to delivery (Asemi et al., 2014). Some studies prescribed combination of vitamin D~3~ with other dietary supplements including vitamin C and calcium. This co-administration improved Glutathione (GSH) activity (Ekici et al., 2009) and decreased oxidative DNA damage in the normal colorectal mucosa (Fedirko et al., 2010). It is proposed, simultaneous prescription of them may lead to the supplementary benefit in TAC increment.

The results are controversial about the impact of vitamin D supplementation on inflammatory markers and TAC with regard to VDR genes. These incompatible outcomes may be attributable to the effect of genetic polymorphisms regulating the response to supplementation (Gagnon et al., 2014). VDR gene variation may be the reason of different response to vitamin D (Barry et al., 2014). We showed that individuals with the VDR FokI Ff, TaqI TT/ Tt genotypes had significantly higher TAC in responses to vitamin D~3~ supplementation. Unexpectedly, serum levels of inflammatory markers in subjects with different genotype had no significant changes. On the contrary, de Medeiros showed among elderly women with BB/Bb genotype had lower levels of us-CRP post intervention parallel with increment of TAC levels (de Medeiros Cavalcante et al., 2015). We hypothesized that the elevation of TAC concentrations with vitamin D~3~ supplementation might be effective in inhibition of oxidative stress in the subgroup of patients with FokI Ff, TaqI TT/ Tt while not effective in patients with the FokI ff, TagI tt, ApaI, BsmI genotypes in our population.

Vitamin D has long been known for its important role in calcium and phosphate homeostasis. Recently, It was demonstrated that receptors of vitamin D decrease the activity of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), the pro-inflammatory transcription factor. This note demonstrates that vitamin D nuclear receptor plays a crucial role in the innate immune response (Adorini et al., 2007; Szeto et al., 2007). Several researchers have shown that the VDR genotype may control the inflammatory marker profile and the anti-inflammatory response to treatment with vitamin D. A clinical trial has demonstrated that the VDR BsmI BB genotype may change the inflammatory marker profile and the anti-inflammatory response to treatment with vitamin D (Shab-Bidar et al., 2015b). Cachectic cancer patients with TT and bb genotype were higher CRP levels than tt/Tt and BB/Bb genotype (Punzi et al., 2012). In contrast, the oxidative stress parameters including MDA (malondialdehyde), GSH and TAC in type 2 diabetic subjects treated with vitamin D for 12 weeks showed no significant differences in FokI genotype, although ff variant subgroup showed the weakest response to vitamin D (Shab-Bidar et al., 2015a).

Some drawbacks of our study need to be mentioned. Due to some limitations, we could not assess the effect of vitamin D supplementation on other biomarkers of inflammation, including hs-CRP, IL-1, and IL-6, as well as enzyme superoxide dismutase, glutathione, and malondialdehyde. The sample size is relatively small and further research with larger sample size should be done.

Our findings indicated that individuals with VDR TT/Tt, and Ff genotype can be regarded as the high responders to vitamin D supplementation regarding body total antioxidant capacity. The prevalence of different VDR variants among breast cancer women could explicate, in part, certain inconsistencies seen in the response to vitamin D in several markers of breast cancer. Further studies are needed to follow this intervention in larger populations, on different biomarkers, and other racial groups to illuminate chemopreventive potency of vitamin D on inflammation, oxidative stress markers and genetic interactions.
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